Skip to main content
Premium Trial:

Request an Annual Quote

NSF Revises Integrative Biological Research Program Solicitation; Award $6.4M to 10 Proposals

NEW YORK, June 23 (GenomeWeb News) - The National Science Foundation revised a previously issued program solicitation for its Frontiers in Integrative Biological Research program.


NSF expects to award approximately $6.4 million to fund ten new proposals. Award size will vary by the project and will be up to five years. Funding decisions will be made by July 2007. The awards are expected to start by September 2007.


FIBR supports "integrative research that addresses major questions in the biological sciences," the NSF said on its web site. The program stresses integrative and interdisciplinary approaches, drawing on tools and concepts from fields like math and physical sciences, engineering, social sciences, and information sciences.


The program does not support research with disease related goals, such as etiology, diagnosis and treatment of human and animal diseases, or drug testing.


The document, NSF 06-579, made four revisions to the previous solicitation, NSF 05-597. They include changes to proposal submission date and new length requirements for the preliminary proposals.


Preliminary proposals are now due Sept. 26. After a review by a panel of outside experts, selected teams will be invited to submit full proposals via FastLane or by Feb. 16, 2007.






The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.